Head and neck cancers are among the most difficult to treat. They can be aggressive and are located near some of the body's ...

Uppaluri R, Campbell KM, Egloff AM, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus–unrelated head and neck cancer: a multicenter, phase II trial.

Talking to loved ones about a recent head and neck cancer diagnosis can be overwhelming. Of course, there is no one "right" ...

Vietnam Head and Neck Cancer Diagnostics Market Key Takeaways: The Vietnam head and neck cancer diagnostics market are witnessing significant growth attributed to several factors. The increasing ...

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care radiotherapy improves event-free survival in patients with resectable, locally ...

Proper nutrition is important for people diagnosed with cancer, both to help them feel better and to assist them in ...

Therapeutics Market is estimated to be valued at USD 2.0 billion in 2025 and is projected to reach USD 6.2 billion by 2035, registering a compound annual growth rate (CAGR) of 12.1% over the forecast ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the US Food and Drug Administration for the treatment of patients with resectable locally advanced head and neck squamous cell ...

Locally advanced (generally stage 3) head and neck squamous cell carcinoma is cancer that has grown outside its original location but has not yet spread to distant sites. It can be challenging to ...

Neoadjuvant and adjuvant pembrolizumab added to standard care significantly improves event-free survival in HNSCC.

For the breakthrough perioperative head and neck cancer indication, Keytruda is only allowed in patients with PD-L1-positive tumors.